Last checked at 
PureTech Health PLC - Massachusetts, US-based biotechnology company - Says its founded entity Vedanta Biosciences's phase 2 clinical trial of VE303 met its primary endpoint of preventing disease recurrence through week 8. VE303 is an orally administered investigational live biotherapeutic product in development for the prevention of recurrent C difficile infection. VE303 achieved a 32% absolute risk reduction in rate of recurrence when compared with placebo, representing a greater than 80% reduction in the odds of a recurrence.
Based on the phase 2 data, the Biomedical Advanced Research & Development Authority has exercised its first contract option for additional funding of USD23.8 million, pursuant to its existing 2020 contract with Vedanta, to support the phase 3 clinical trial of VE303, which Vedanta plans to initiate in 2022.
Current stock price: 343.00 pence
Year-to-date change: down 14%
By Evelina Grecenko; evelinagrecenko@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
